vs

Side-by-side financial comparison of Allison Transmission Holdings Inc (ALSN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Allison Transmission Holdings Inc is the larger business by last-quarter revenue ($737.0M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 13.4%, a 21.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -7.4%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -3.4%).

Allison Transmission Holdings Inc. is an American manufacturer of commercial duty automatic transmissions and hybrid propulsion systems. Allison products are specified by over 250 vehicle manufacturers and are used in many market sectors, including bus, refuse, fire, construction, distribution, military, and specialty applications.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

ALSN vs RPRX — Head-to-Head

Bigger by revenue
ALSN
ALSN
1.2× larger
ALSN
$737.0M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+12.2% gap
RPRX
4.8%
-7.4%
ALSN
Higher net margin
RPRX
RPRX
21.0% more per $
RPRX
34.4%
13.4%
ALSN
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-3.4%
ALSN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALSN
ALSN
RPRX
RPRX
Revenue
$737.0M
$622.0M
Net Profit
$99.0M
$214.2M
Gross Margin
48.0%
Operating Margin
23.2%
62.4%
Net Margin
13.4%
34.4%
Revenue YoY
-7.4%
4.8%
Net Profit YoY
-43.4%
2.9%
EPS (diluted)
$1.18
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALSN
ALSN
RPRX
RPRX
Q4 25
$737.0M
$622.0M
Q3 25
$693.0M
$609.3M
Q2 25
$814.0M
$578.7M
Q1 25
$766.0M
$568.2M
Q4 24
$796.0M
$593.6M
Q3 24
$824.0M
$564.7M
Q2 24
$816.0M
$537.3M
Q1 24
$789.0M
$568.0M
Net Profit
ALSN
ALSN
RPRX
RPRX
Q4 25
$99.0M
$214.2M
Q3 25
$137.0M
$288.2M
Q2 25
$195.0M
$30.2M
Q1 25
$192.0M
$238.3M
Q4 24
$175.0M
$208.2M
Q3 24
$200.0M
$544.0M
Q2 24
$187.0M
$102.0M
Q1 24
$169.0M
$4.8M
Gross Margin
ALSN
ALSN
RPRX
RPRX
Q4 25
48.0%
Q3 25
47.5%
Q2 25
49.4%
Q1 25
49.3%
Q4 24
46.9%
Q3 24
48.1%
Q2 24
48.3%
Q1 24
46.4%
Operating Margin
ALSN
ALSN
RPRX
RPRX
Q4 25
23.2%
62.4%
Q3 25
29.4%
70.1%
Q2 25
31.4%
36.3%
Q1 25
32.5%
94.0%
Q4 24
29.5%
60.9%
Q3 24
31.6%
Q2 24
32.2%
50.2%
Q1 24
29.7%
-13.0%
Net Margin
ALSN
ALSN
RPRX
RPRX
Q4 25
13.4%
34.4%
Q3 25
19.8%
47.3%
Q2 25
24.0%
5.2%
Q1 25
25.1%
41.9%
Q4 24
22.0%
35.1%
Q3 24
24.3%
96.3%
Q2 24
22.9%
19.0%
Q1 24
21.4%
0.8%
EPS (diluted)
ALSN
ALSN
RPRX
RPRX
Q4 25
$1.18
$0.49
Q3 25
$1.63
$0.67
Q2 25
$2.29
$0.07
Q1 25
$2.23
$0.55
Q4 24
$2.01
$0.46
Q3 24
$2.27
$1.21
Q2 24
$2.13
$0.23
Q1 24
$1.90
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALSN
ALSN
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$1.5B
$618.7M
Total DebtLower is stronger
$2.9B
$9.0B
Stockholders' EquityBook value
$1.9B
$9.7B
Total Assets
$6.1B
$19.6B
Debt / EquityLower = less leverage
1.56×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALSN
ALSN
RPRX
RPRX
Q4 25
$1.5B
$618.7M
Q3 25
$902.0M
$938.9M
Q2 25
$778.0M
$631.9M
Q1 25
$753.0M
$1.1B
Q4 24
$781.0M
$929.0M
Q3 24
$788.0M
$950.1M
Q2 24
$648.0M
$1.8B
Q1 24
$551.0M
$843.0M
Total Debt
ALSN
ALSN
RPRX
RPRX
Q4 25
$2.9B
$9.0B
Q3 25
$2.4B
$8.9B
Q2 25
$2.4B
$8.0B
Q1 25
$2.4B
$7.6B
Q4 24
$2.4B
$7.6B
Q3 24
$2.4B
$7.6B
Q2 24
$2.4B
$7.6B
Q1 24
$2.4B
$6.1B
Stockholders' Equity
ALSN
ALSN
RPRX
RPRX
Q4 25
$1.9B
$9.7B
Q3 25
$1.8B
$9.6B
Q2 25
$1.8B
$9.5B
Q1 25
$1.7B
$9.8B
Q4 24
$1.7B
$10.3B
Q3 24
$1.6B
$10.3B
Q2 24
$1.5B
$9.8B
Q1 24
$1.3B
$9.9B
Total Assets
ALSN
ALSN
RPRX
RPRX
Q4 25
$6.1B
$19.6B
Q3 25
$5.5B
$19.3B
Q2 25
$5.4B
$18.3B
Q1 25
$5.4B
$17.6B
Q4 24
$5.3B
$18.2B
Q3 24
$5.4B
$18.0B
Q2 24
$5.2B
$17.7B
Q1 24
$5.1B
$16.1B
Debt / Equity
ALSN
ALSN
RPRX
RPRX
Q4 25
1.56×
0.92×
Q3 25
1.31×
0.93×
Q2 25
1.38×
0.84×
Q1 25
1.45×
0.78×
Q4 24
1.46×
0.74×
Q3 24
1.49×
0.74×
Q2 24
1.63×
0.78×
Q1 24
1.80×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALSN
ALSN
RPRX
RPRX
Operating Cash FlowLast quarter
$243.0M
$827.1M
Free Cash FlowOCF − Capex
$169.0M
FCF MarginFCF / Revenue
22.9%
Capex IntensityCapex / Revenue
10.0%
Cash ConversionOCF / Net Profit
2.45×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$661.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALSN
ALSN
RPRX
RPRX
Q4 25
$243.0M
$827.1M
Q3 25
$228.0M
$702.6M
Q2 25
$184.0M
$364.0M
Q1 25
$181.0M
$596.1M
Q4 24
$211.0M
$742.5M
Q3 24
$246.0M
$703.6M
Q2 24
$171.0M
$658.2M
Q1 24
$173.0M
$664.6M
Free Cash Flow
ALSN
ALSN
RPRX
RPRX
Q4 25
$169.0M
Q3 25
$184.0M
Q2 25
$153.0M
Q1 25
$155.0M
Q4 24
$136.0M
Q3 24
$210.0M
Q2 24
$150.0M
Q1 24
$162.0M
FCF Margin
ALSN
ALSN
RPRX
RPRX
Q4 25
22.9%
Q3 25
26.6%
Q2 25
18.8%
Q1 25
20.2%
Q4 24
17.1%
Q3 24
25.5%
Q2 24
18.4%
Q1 24
20.5%
Capex Intensity
ALSN
ALSN
RPRX
RPRX
Q4 25
10.0%
Q3 25
6.3%
Q2 25
3.8%
Q1 25
3.4%
Q4 24
9.4%
Q3 24
4.4%
Q2 24
2.6%
Q1 24
1.4%
Cash Conversion
ALSN
ALSN
RPRX
RPRX
Q4 25
2.45×
3.86×
Q3 25
1.66×
2.44×
Q2 25
0.94×
12.06×
Q1 25
0.94×
2.50×
Q4 24
1.21×
3.57×
Q3 24
1.23×
1.29×
Q2 24
0.91×
6.45×
Q1 24
1.02×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALSN
ALSN

North America On Highway$361.0M49%
Service Parts Support Equipment And Other$160.0M22%
Outside North America On Highway$131.0M18%
Defense$73.0M10%
Global Off-Highway$12.0M2%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons